Patient characteristics and disease activity measures at baseline and 1 year of 327 polyarticular JIA patients and a weighted RA cohort starting first TNFi
| Median (IQR) or % | Polyarticular JIA | RA (weighted analysis) | p Value (JIA compared with RA) |
|---|---|---|---|
| Gender, female | 85% | 85% | 1.000 |
| Age at treatment start, years | 32 (24–42) | 32 (24–42) | 0.928 |
| Age at disease onset, years | 13 (8–15) | 25 (20–34) | 0.001 |
| Disease duration, years | 22 (14–32) | 5 (2–10) | 0.001 |
| Ethnicity; white | 95% | 93% | 0.215 |
| On methotrexate | 57% | 67% | 0.005 |
| On steroids | 42% | 42% | 0.956 |
| RF positive | 46% | 60% | 0.001 |
| TNFi at registration (%) | 0.002 | ||
| Etanercept | 42 | 34 | |
| Infliximab | 29 | 26 | |
| Adalimumab | 27 | 32 | |
| Certolizumab | 2 | 7 | |
| Total comorbidities* (%) | 0.377 | ||
| None | 56 | 60 | |
| 1 | 30 | 27 | |
| ≥2 | 14 | 13 | |
| Smoking status (%) | 0.397 | ||
| Current smoker | 22 | 22 | |
| Previous smoker | 19 | 23 | |
| Never smoked | 59 | 55 | |
| DAS28 | |||
| Baseline | 6.3 (5.6–7.0) | 6.3 (5.6–6.9) | 0.992 |
| 1 year | 3.9 (2.8–5.0) | 3.8 (2.5–5.1) | 0.991 |
| Change in DAS28 at 1 year | −2.4 (−3.4 to −1.3) | −2.6 (−3.6 to −1.2) | 0.589 |
| EULAR response (%) at 1 year | 0.359 | ||
| No response | 19 | 20 | |
| Moderate | 50 | 43 | |
| Good | 31 | 37 | |
| DAS28 remission (%) at 1 year | 23 | 26 | 0.539 |
| HAQ | |||
| Baseline | 2.0 (1.6–2.4) | 1.9 (1.4–2.3) | 0.005 |
| 1 year | 1.6 (1.0–2.1) | 1.4 (0.8–2.0) | 0.033 |
| Change in HAQ at 1 year | −0.4 (−0.8 to −0.1) | −0.5 (−0.8 to −0.1) | 0.523 |
| HAQ MCID (%) at 1 year | 64 | 66 | 0.775 |
*Comorbidities include; hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic bronchitis/emphysema, peptic ulcer, liver disease, renal disease, tuberculosis, demyelination, diabetes, hyperthyroidism, depression, cancer.
DAS28, 28-joint Disease Activity Score; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JIA, Juvenile Idiopathic Arthritis; MCID, Minimally Clinical Important Difference; RA, Rheumatoid Arthritis; RF, Rheumatoid factor; TNFi, tumour necrosis factor inhibitor.